
|Articles|November 7, 2012
Dermatology drug developer raises $16M
Thesan Pharmaceuticals has been given $16 million in series A funding to develop novel treatments for inflammatory skin disorders.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
KT-621 Produces 98% STAT6 Degradation in AD Patients
2
Transparency Gaps in Prior Authorization Denials and Their Impact on Dermatologic Care
3
AI at the Bedside: How Automated Solutions are Transforming Vitiligo Management
4
Celebrating a Year of Growth and Research
5



















